Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma

Xue Zhang¹,², Qiao-Li LV¹,², Yuan-Tao Huang¹,²,³, Li-Hua Zhang¹,² and Hong-Hao Zhou¹,²*

Abstract

Background: MYB-related protein B (B-MYB/MYBL2), a member of the myeloblastosis family of transcription factors, has been reported for its role in the genesis and progression of tumors. Forkhead box M1 (FoxM1), another transcriptional factor, is considered to be an independent predictor of poor survival in many solid cancers. The aim of the present study was to investigate the clinical significance of the correlation between MYBL2 and FoxM1 in glioma and the possible mechanism of FoxM1 and MYBL2 expression.

Methods: MYBL2 and FoxM1 expression in cancerous tissues and cell lines were determined by reverse transcription-PCR (RT-PCR), Western blotting and immunostaining. The co-expression of MYBL2 and FoxM1 was analyzed in low-grade glioma (LGG) and glioblastoma (HGG) cohorts of TCGA using cBioportal and UCSC Xena. And, the role of MYBL2 and FoxM1 in glioma cell progression and the underlying mechanisms were studied by using small interfering RNA (si-RNA) and pcDNA3.1 + HA vectors. Furthermore, the effects of MYBL2 and FoxM1 in cell proliferation, cell cycle progression, apoptosis, migration, invasion, and adhesion were determined by cell proliferation assays, flow cytometry analysis, transwell migration and cell adhesion assay.

Results: MYBL2 and FoxM1 expression are significantly associated with clinical stages and overall survival of glioma patients. In cohorts of TCGA, patients with high MYBL2 but without radio-chemotherapy had the highest hazard ratio (adjusted HR = 5.29, 95% CI = 1.475–18.969, P < 0.05). Meanwhile, MYBL2 closely related to the FoxM1 expression in 79 glioma tissues (r = 0.742, p < 0.05) and LGG (r = 0.83) and HGG (r = 0.74) cohorts of TCGA. Down regulation of FoxM1 and MYBL2 by siRNAs induced the cell cycle arrest, apoptosis and EMT of glioma cells. Furthermore, inactivations of Akt/FoxM1 signaling by Akt inhibitor and siRNA-FoxM1 reduce the expression of MYBL2 in glioma cells.

Conclusions: MYBL2 is a key downstream factor of Akt/FoxM1 signaling to promote progression of human glioma, and could be a new candidate gene for molecular targeting therapy and biomarker for radiotherapy of glioma.

Trial registration: CTXY-1300041-3-2. ChiCTR-COC-15006186. Registered date: 13 September 2013.

Keywords: Glioma, FoxM1, MYBL2, Progression
Background

Gliomas are the most common form of primary brain tumor in the adult central nervous system [1]. Although recent studies showed progress in both diagnostic modalities and therapeutic strategies, glioma remains one of the deadliest human cancers. The five-year survival rate of patients with glioma is the lowest among those of all cancers [2, 3]. The alternative treatment for glioma is limited due to the unclear pathophysiological mechanisms underlying the development of this disease. Therefore, understanding the molecular mechanism of the development and progression of glioma will shed light on strategies for accurate diagnosis, early intervention, and effective therapies.

Transcription factors (TFs) play important roles in the transcriptional networks that regulate gene expression, and misregulation of these TFs can result in the acquisition of tumor-related properties [4]. Differentially expressed TFs in glioblastoma, and their downstream gene targets may be potential therapeutic biomarkers of glioblastoma [5]. The MYBL2 gene, which is also known as B-MYB, is a member of the myeloblastosis family of transcription factors, first identified as cellular homologues of the v-myb oncogene that is known to cause leukemia in chickens [6]. MYBL2 of proliferative cells is crucial for the regulation of proliferation and differentiation, and also has a vital role in guiding cell cycle progression [7]. Meanwhile, MYBL2 amplification or overexpression has been observed in cancers such as myeloid leukemias (AML) [8], hepatocellular carcinoma [9], breast cancer [10], and it is currently used as a marker for poor prognosis in colorectal carcinoma [11]. However, it is still not clear about the role of the MYBL2 gene in glioma.

FoxM1 is a member of the Forkhead box (Fox) transcription factor family, which has been shown to be over-expressed in various cancers and studies have shown that alterations in FoxM1 signaling were associated with carcinogenesis. FoxM1 is substantially elevated in several aggressive human carcinomas and can contribute to oncogenesis in many tissue types, including breast [12], hepatocellular [13], prostate [14], lung [15], and colorectal cancers [16]. Aberrant FoxM1 expression was found to be a common molecular alteration in malignant glioma [17]. Moreover, it has been shown that higher expression of FoxM1 was associated with poor prognosis and radio resistance in glioma patient [18–20]. Previous studies showed that FoxM1 was a key downstream gene of the Akt/FoxM1 signaling cascade [21]. Another finding suggested that Akt/FoxM1 signaling played an impotent role in cervical cancer cell growth and treatment [22]. However, the role and mechanism of Akt/FoxM1 signaling in the development of glioma is unknown.

Here, we have thoroughly investigated the expression levels of MYBL2 in glioma tissues and cell lines. And, we sought to determine whether Akt/FoxM1 signaling pathway is involved in regulating MYBL2 expression and whether these factors can predict the disease progression and prognosis of the glioma patients.

Methods

Patient samples

All samples, along with available clinical-pathological data, were obtained from were obtained from Xiangya Hospital of Central South University (Changsha, Hunan, China) between 2013 and 2014, with written informed consent. All pathological features were confirmed by experienced pathologists, and none of the patients received pre-operative anti-cancer treatment. All procedures were approved by the Ethics Committee Institute of Clinical Pharmacology, Central South University (Ethical Approval No. CTXY-1300041-3). These patients 79 had completed a follow-up time along with 48 months from the date of surgical resection. Overall survival (OS) was defined as a period time between the date of the initial surgical operation and death or the last follow-up.

Bioinformatic data mining

We downloaded RNA-Seq gene expression data (Level 3) and clinical data from the TCGA data portal (https://gdc-portal.nci.nih.gov/) as our other source of samples, and a total of 567 tumors having clinical data were profiled for class discovery and survival analysis [23]. For overall survival (OS) and relapse-free survival (RFS) were searched in the glioma patient cohort in TCGA database using cBioportal (http://cBioportal.org). The heat map and the correlation betweenMYBL2 and FoxM1 genes in the same patient cohort were further verified and analyzed using UCSC Xena t (http://xena.ucsc.edu/). Moreover, the molecular functional network map of canonical pathways including coexpression, physical interaction, and predicted networks of FoxM1 analyzed by GeneMANIA (http://genemania.org/).

Cell culture

Penicillin, streptomycin, trypsin-EDTA (ethylene diaminetetra acetic acid) were purchased from Beyotime (Beijing, China). The human glioma cell lines U251, U343, U87, T98G, and Hs683 were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in and cultured in DMEM (Invitrogen, Shanghai, China), containing 10% fetal bovine serum (Gibco, Logan, UT, USA) and 100 U penicillin and streptomycin at 37 °C in a humidified atmosphere containing 5% CO₂.
Cell transfection
Three different interfering RNA (siRNA) for the specific inhibition of MYBL2 and FoxM1 expression and a negative control siRNA were synthesized by GenePharma Co., Ltd. (Shanghai, China). Exponentially growing untreated cells were plated 24 h before transfection. Plated cells were transfected with FoxM1 siRNA or MYBL2 siRNA at a final concentration of 50 nM, using 5 μL Lipo-RNAiMAX following the manufacturer’s instructions (Invitrogen, USA). After treatment, the cells were harvested and processed for further analysis. Human FoxM1 gene was inserted in pcDNA3.1 + HA vector and MYBL2 was inserted in GV230- GFP by Life Technologies (Shanghai Genechem Co., Ltd., Shanghai, China) and the empty vector was used as the negative control. Hs683 cells transfected with FoxM1 and MYBL2 vectors with Lipofectamine 2000 according to the manufacturer’s information.

RNA extraction and quantitative real-time PCR (RT-qPCR)
Total RNA was extracted from cultured cells or tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. First-strand cDNA synthesis was performed using Prime Script RT Master Mix (TaKaRa Biotechnology Co., Ltd., Dalian, China). Real-time quantitative PCR was performed using a standard SYBR Green PCR kit (Thermo). All reactions were conducted using the following cycling parameters: 95 °C for 2 min, followed by 40 cycles of 95 °C for 15 s, with a final extension at 60 °C for 60 s. GAPDH was used as an endogenous control. The gene expression was calculated using the ΔΔCt method. All data represent the average of three replicates. The primers used are listed in Table 1.

Cell viability and proliferation assays
Cell viability and proliferation were measured by MTT assay after treatment. The identified cells were seeded in 96-well plates (6 × 10^3 cells/well) and transfected with siRNAs. After culturing cell for an appropriate time, 50 μL of 5 mg/ml MTT (Sigma) was added to each well and cultured for 4 h. Then, the cell culture medium was replaced by 100 μL of dimethyl sulfoxide. After 2–3 h of incubation at 37 °C, the number of viable growing cells was estimated by measuring absorption at 570 nm wavelength and cell growth curves were determined according to the optical density value. The proliferation rate was calculated using the following formula: proliferation rate = survival rate = (OD test/OD negative control) × 100%. All experiments were performed in triplicate and repeated at least three times.

Cell cycle analysis
Propidium iodide (PI) staining was used to analyze DNA content. Treated and untreated cells were harvested and labeled with PI by using previously described methods. Briefly, Cells in each group were washed with PBS for twice and centrifuged at 5000 rpm for 7 min to regulate the density as 1 × 10^6 cells/well. Then, pre-cooling 70% ethyl alcohol was added for fixation overnight at ~20 °C. On the next day, the fixed cells were washed with PBS, incubated with 400 μl PI/ RNase Staining Buffer (BD Company) at room temperature in the dark for 15 min. The cell cycle distribution was determined using a flow cytometer (Beckman Coulter, Brea, CA, USA). We then determined the percentage of cells in the G0/G1, S, and G2/M phases with the FlowJo software (Tree Star). The experiment was repeated for three times.

Apoptosis analysis
Apoptosis was assayed by Annexin V staining and flow cytometry analysis. Briefly, 3 × 10^5 cells were harvested, washed in PBS, and then analyzed by Annexin V/ propidium iodide staining according to the manufacturer’s protocol (FITC-Annexin V kit; BD Pharmingen, San Diego, CA). The stained cells were analyzed by flow cytometry.

Colony formation and clonogenic assays
U251 cells were seeded in 6-well plates (1.5 × 10^3 cells/well); transfected with a non- silencing control siRNA, MYBL2 siRNA, or FoxM1 siRNA. After 15 days of incubation in the incubator, cell colonial forming amount was observed under the inverted microscope. And then, the cells were washed with PBS and stained with crystal violet, and visible colonies were counted.

Table 1 Oligonucleotide primer sequences used in the qRT-PCR

| Gene     | Forward                      | Reverse                      |
|----------|------------------------------|------------------------------|
| MYBL2    | 5'-CTTGAGCGAGGTCAAGAGACTG-3' | 5'-AGTTGCTGAGAAGACTCCCT-3'   |
| FOXM1    | 5'-ATACGTGGGAGGAGACCACT-3'   | 5'-TCACATTGCTCAATGAGGGTTG-3' |
| Akt      | 5'-GATCTACTGCTGGAGAAGA-3'    | 5'-TGGTATCTTAAATGTGCCCCGT-3' |
| GAPDH    | 5'-CCCATCACCTCTCCAGGAG-3'    | 5'-CTCTCATGTTGGTGAAGACG-3'   |
| β-actin  | 5'-CATGTAAGTTGCTATCCAGG-3'   | 5'-CTCCATACGAGCG-3'          |

The specific oligonucleotide primer sequences are listed in Table 1. GAPDH and β-actin were used as internal controls and the qRT-PCR result was quantified by 2^−ΔΔCT method.
Cell migration and motility
Cells were seeded in six-well plates (5 x 10^5 cells/well) and 24 h later were transfected with the control siRNA, MYBL2 siRNA (50 nM) or FoxM1 siRNA (50 nM). After culturing cell for an appropriate time, artificial wounds were gently made using a micropipette tip, and the cells were washed with PBS to remove floating cells and debris. The cells were then incubated in serum-free medium. Cells in the scratched area were imaged at 0 and 48 h using microscopy, and the distance traveled by cells at the leading edge of the wound at each time point was measured. The results were expressed as percent migration.

Transwell migration and invasion assays
Cell migration and invasion were assessed using a transwell assay. For migration assays, Matrigel (1:8) (BD Biosciences, Bedford, MA, USA) was diluted with serum-free DMEM, and the basement membrane of the upper chamber of the transwell was coated. The solution was kept at 37 °C for 1–4 h to transform the Matrigel aggregate into the gel. Treated cells were harvested and aggregate into the gel. Treated cells were harvested and incubated with 3% heat-denatured BSA to block any unoccupied areas. Cells were cultured in a 5% CO₂ incubator at 37 °C for 24 h [24]. The culture medium in each well was then discarded, and the chamber was washed twice with PBS. And gently removing the cells in the upper chamber with a cotton swab, the cells on the underside of the membrane were fixed with 4% paraformaldehyde for 15 min, stained with 0.1% cresyl violet, washed three times with PBS, and air-dried. Five fields (200 × magnification) were randomly selected for counting the number of migrated cells, and images were taken by using phase contrast microscopy.

Cell adhesion assay
Ninety-six-well dishes were pre-coated with 30 mg/L fibronectin solution (50 μL/well), then air-dried at room temperature overnight, and then rinsed with PBS and incubated with 3% heat-denatured BSA to block any uncoated areas. Cells were cultured in a 5% CO₂ incubator at 37 °C for 1 h. The culture solution was then removed from the 24-well plate, and non-adherent cells were washed away three times with PBS. The remaining cells were fixed for 30 min with 4% paraformaldehyde, stained with cresyl violet for 15 min, and observed under an inverted microscope.

IHC
TMA slides were processed and stained manually as described previously. Formalin-fixed, paraffin-embedded sections were prepared for all tissues. Sections were deparaffinized in xylene and rehydrated through graded alcohol to water, and endogenous peroxidase activity was blocked by incubating the slides in 3% H₂O₂ in water for 30 min at room temperature. Sections were incubated in 1% BSA for 30 min then wiped off and dilution of MYBL2 (1:200, Santa Cruz) and FoxM1 (1:200, Santa Cruz) were applied to the slides and incubated overnight at room temperature. Subsequently, sections were incubated with secondary antibody for 2 h at room temperature, according to the manufacturer’s instructions. Negative control slides were processed in parallel using a non-specific immunoglobulin IgG (Sigma Chemical Co, St. Louis, MO, USA) at the same concentration as the primary antibody. Stained sections were observed under a microscope. Only fresh cut slides were stained simultaneously to minimize the influence of slide ageing and maximize repeatability and reproducibility of the experiment.

Immunofluorescence double staining
U251 cells were planted on glass slides in a 6-well at a density of 1 x 10⁶ cells per well. Treated and untreated cells were fixed with ice-cold 4% paraformaldehyde for 30 min, permeabilised with 0.1% Triton X-100, and blocked in 2% gelatin in PBS at room temperature. Cells were then incubated with MYBL2 (Millipore, USA, 1:500) and FoxM1 (Cell Signaling Technology, USA, 1:500) primary antibodies at 4 °C overnight. After being washed, the cells were incubated with secondary antibody (1:100) for 1 h at room temperature. The cell nucleus showed blue fluorescence (stained by DAPI). Images were obtained under a fluorescence microscope.

Western blot analysis
Cells from each group were collected, and whole-cell lysates were generated using RIPA lysis buffer (Abcam, Cambridge, UK). The protein concentration was detected by BCA method (U.S. Pierce Company). Total proteins were separated using 10% or 12% SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane was incubated with the primary antibody at 4 °C overnight, followed by a horseradish peroxidase-conjugated secondary antibody the next day for 2 h at room temperature. β-actin and GAPDH were purchased from (Sigma, USA). MYBL2 was purchased from (Millipore, USA). P-Akt and p-38 MAPK were purchased from (Santa Cruz Biotechnology, USA). SC79 (Akt activator) and MK-2206 (Akt inhibitor) were purchased from Selleck (Beijing, China). E-Cadherin (Wanleibio, China). Cyclins (CDK2, CDK6, CyclinD1, CyclinD3, CDK4, etc.), FoxM1, ZEB1, MMP9, MMP2, Vimentin and N-Cadherin were purchased from Cell Signaling Technology (Danvers, MA, USA).
Statistical analysis
Statistical significance between different groups was determined using t-tests for the MYBL2 and FoxM1 mRNA levels analysis and cell assay. Kaplan-Meier survival curves were used to compare survival rates. Univariate and multivariate Cox proportional hazard models were used to explore the associations between patient characteristics and biomarkers with outcomes. Statistical analyses were performed using SPSS19.0 software (IBM, Chicago, IL, USA). Data are shown as mean ± standard deviation. P-values <0.05 differences was considered statistically significant.

Results
Association of MYBL2 and FoxM1 with glioma risk
To determine whether MYBL2 and FoxM1 were differentially expressed between glioma and normal tissues, the mRNA expressions were analyzed by qRT-PCR in 79 glioma and 9 normal tissues. Both MYBL2 and FoxM1 levels were significantly higher in glioma than in normal tissues, similar to the IHC results (Fig. 1b and c). We then divided the glioma patients into different groups based on the mean value (3.83) of relative MYBL2 and the mean value (5.88) of relative FoxM1 expression. We found that MYBL2 and FoxM1 expression had a close correlation with the tumor progression: both genes were higher expression in patients with advanced tumor stage than in normal tissues (*P < 0.05) and early-stage (*P < 0.05). But the tumor progression was not correlated with patient’s age, gender and tumor location (P > 0.05, Tables 2 and 3).

To further confirm the association of MYBL2 and FoxM1 with glioma risk, we analyzed the gene expression...
data of glioma cases in the high-grade glioma (HGG) TCGA data set, which includes 567 glioma tissues and 10 non-tumor tissues. MYBL2 and FoxM1 mRNA expression were found to be significantly increased (MYBL2, $P < 0.001$; FoxM1, $P < 0.001$) in HGG compared to normal brain (Fig. 1a). The characteristics and clinical features of 567 high-grade glioma patients are shown in Additional file 1: Table S1.

MYBL2 and FoxM1 overexpression linked with poor outcome

We evaluated the effects of MYBL2 and FoxM1 on overall survival of the glioma patients using Kaplan-Meier analysis and log-rank test. In 79 glioma cases, MYBL2 and FoxM1 expression were significantly associated with glioma patients’ overall survival (OS) (MYBL2, $P < 0.001$; FoxM1, $P < 0.001$, Fig. 2b). Univariate Cox regression analysis indicated that the clinical stage (HR = 1.833, 95% CI: 1.395–2.409, $p < 0.001$) and high expression of MYBL2 (HR = 3.619, 95% CI: 2.075–6.313, $p < 0.001$) and FoxM1 (HR = 0.336, 95% CI: 0.187–0.602, $p < 0.001$) were unfavorable prognostic factors in glioma patients (Tables 4 and 5).

To confirm the association of these gene signatures with the outcome, we compared OS (overall survival) and DFS (disease free survival) between patients with higher expression levels and patients with lower expression levels of MYBL2 and FoxM1 genes in low-grade glioma (LGG) and glioblastoma (HGG) cohorts of TCGA using cBioPortal. Kaplan-Meier survival curves show that patients with lower expression levels of MYBL2 or FoxM1 have better OS and DFS prognoses than those with higher expression levels in LGG group (Fig. 2b and c, log-rank test, unadjusted $P$-value <0.05). Though there is no significant difference, patients with lower expression levels of MYBL2 or FoxM1 have better OS and DFS prognoses than those with higher expression levels (Fig. 2d and e, log-rank test, unadjusted $P$-value >0.05). These results indicated that low expression of MYBL2 and FoxM1 probably confer a survival advantage to glioma patients.

MYBL2 is a radiosensibility biomarker of glioma

To further characterize the association of MYBL2 and FoxM1 with glioma survival, we analyzed the interaction of MYBL2 and FoxM1 with radiotherapy status in HGG cohorts of TCGA, and observed that compared to patients with MYBL2 over-expression and radiotherapy, those with MYBL2 over-expression but without radiotherapy had a significantly higher death risk (adjusted HR = 5.29, 95% CI = 1.475–18.969, $P < 0.05$) (Tables 6 and 7). These results suggesting that in high-grade glioma, MYBL2 gene over-expression might identify

---

**Table 2** Correlation between MYBL2 expression and clinicopathological features in 79 glioma patients

| Clinical characteristic | NO. of patients | NO. of patients | $P$ Value |
|-------------------------|----------------|----------------|-----------|
|                        | High expression (n=24) | Low expression (n=55) | |
| Age (year)             |               |                |           |
| $\geq$45                | 30            | 21             | 0.474524  |
| <45                     | 49            | 34             |           |
| Sex                     |               |                |           |
| Male                    | 50            | 35             | 0.329518  |
| Female                  | 29            | 20             |           |
| Clinical Stage          |               |                |           |
| Low grades I-II         | 35            | 31             | <0.001    |
| High grades III - IV    | 44            | 24             |           |
| Tumor location          |               |                |           |
| Frontal                 | 34            | 24             | 0.738     |
| Parietal                | 13            | 8              |           |
| Occipital               | 1             | 0              |           |
| Temporal                | 18            | 14             |           |
| Others                  | 13            | 9              |           |

**Table 3** Correlation between FoxM1 expression and clinicopathological features of glioma patients

| Clinical characteristic | NO. of patients | NO. of patients | $P$ Value |
|-------------------------|----------------|----------------|-----------|
|                        | High expression (n=26) | Low expression (n=53) | |
| Age (year)             |               |                |           |
| $\geq$45                | 30            | 17             | 0.102647  |
| <45                     | 49            | 36             |           |
| Sex                     |               |                |           |
| Male                    | 50            | 34             | 0.210681  |
| Female                  | 29            | 19             |           |
| Clinical Stage          |               |                |           |
| Low grades I-II         | 35            | 30             | <0.01     |
| High grades III - IV    | 44            | 23             |           |
| Tumor location          |               |                |           |
| Frontal                 | 34            | 24             | 0.357     |
| Parietal                | 13            | 7              |           |
| Occipital               | 1             | 1              |           |
| Temporal                | 18            | 12             |           |
| Others                  | 13            | 7              |           |
Fig. 2  Survival analyses of cancer patients based on expression of MYBL2 and FoxM1. 

(a) Compare overall survival time between MYBL2 (left) or FoxM1 (right) higher expression levels and lower-expression-level in 79 glioma tissues. 

(b) Compare overall survival time between MYBL2 (left) or FoxM1 (right) higher expression levels and lower expression levels in LGG. 

(c) Associations between MYBL2 (left) and FoxM1 (right) gene expression levels and disease-free survival in LGG. 

(d) Compare overall survival time between MYBL2 (left) or FoxM1 (right) higher expression levels and lower-expression-level in HGG. 

(e) Associations between MYBL2 (left) and FoxM1 (right) gene expression levels and disease-free survival in HGG.
patients who will not benefit from the treatment of radiotherapy.

Altering the expression of MYBL2 and FoxM1 in glioma cells

We performed qRT-PCR analysis and Western blotting to test FoxM1 and MYBL2 expression in high-grade glioma cell lines (U251, U87, U343 and T98G), low-grade cell line (Hs683) and 9 normal tissues. As shown in Fig. 3a (upper), all of the high-grade cell lines exhibited higher mRNA expression of FoxM1 and MYBL2 compared to the normal tissues. Similar results were found in protein level (Fig. 3a).

To investigate the functions of MYBL2 and FoxM1 expression in glioma, we up and down regulated both genes in low and high-grade glioma cells. Firstly, we transected GV230-MYBL2 (2 μg/mL) and pcDNA3.1 + HA-FOXM1 (2 μg/mL) to increase the genes expression in low grade glioma Hs683 cells, respectively. The transfection efficiency of the plasmid vectors was evaluated by real-time PCR and Western blotting (Fig. 3d). Then, we knocked down both genes expression by RNA interference (RNAi) in high-grade glioma cells, including U87, T98G, U343 and U251 cells. The silencing effects of the siRNA were also evaluated by real-time PCR and Western blotting (Fig. 3b and c).

| Table 4 Univariate and multivariate Cox regression of MYBL2 for overall survival in glioma |
|----------------------------------|-----------------|-----------------|-----------------|
| **Variable** | **OS** | **Univariate analysis** | **Multivariate analysis** |
| | | **HR (95% CI)** | **P-value** | **HR (95% CI)** | **P-value** |
| Age (year) <45 vs. ≥45 | 0.874 (0.488-1.567) | 0.652 | 0.873 (0.474-1.606) | 0.873 |
| Gender Female vs. male | 1.038 (0.617-1.746) | 0.889 | 1.021 (0.590-1.767) | 0.941 |
| Clinical Stage III-IV vs. I-II | 1.833 (1.395-2.409) | <0.001 | 0.360 (0.193-0.670) | <0.05 |
| Tumor Location Parietal vs. Frontal | 1.413 (0.715-2.790) | 0.32 | 0.731 (0.324-1.650) | 0.45 |
| Temporal vs. Frontal | 1.173 (0.652-2.110) | 0.594 | 0.995 (0.517-1.914) | 0.966 |
| Others vs. Frontal | 0.605 (0.297-1.232) | 0.166 | 0.335 (0.308-1.493) | 0.301 |
| MYBL2 Expression Low vs. high | 3.619 (2.075-6.313) | <0.001 | 0.354 (0.193-0.650) | <0.05 |

HR hazard ratio; CI confidence interval; MYBL2 MYB-related protein B

| Table 5 Univariate and multivariate Cox regression of FoxM1 for overall survival in glioma |
|----------------------------------|-----------------|-----------------|-----------------|
| **Variable** | **OS** | **Univariate analysis** | **Multivariate analysis** |
| | | **HR (95% CI)** | **P-value** | **HR (95% CI)** | **P-value** |
| Age (year) <45 vs. ≥45 | 0.874 (0.488-1.567) | 0.652 | 0.964 (0.528-1.761) | 0.905 |
| Gender Female vs. male | 0.964 (0.573-1.622) | 0.889 | 1.010 (0.585-1.744) | 0.971 |
| Clinical Stage III-IV vs. I-II | 0.297 (0.172-0.514) | <0.001 | 0.347 (0.188-0.642) | <0.05 |
| Tumor Location Parietal vs. Frontal | 0.708 (0.358-1.398) | 0.32 | 1.068 (0.465-2.454) | 0.876 |
| Temporal vs. Frontal | 0.852 (0.474-1.533) | 0.594 | 1.170 (0.589-2.321) | 0.654 |
| Others vs. Frontal | 1.653 (0.812-3.364) | 0.166 | 1.425 (0.651-3.116) | 0.3754375 |
| FoxM1 Expression Low vs. high | 0.336 (0.187-0.602) | <0.001 | 0.391 (0.196-0.779) | <0.05 |

HR hazard ratio, CI confidence interval, FoxM1 Forkhead box M1
MYBL2 and FoxM1 accelerate tumor progression in glioma

To address the cellular mechanisms of MYBL2 and FoxM1 responsible for tumor progression, MTT assay and colony formation assay were performed. Firstly, we performed foci formation assays as described. In low-grade glioma Hs683 cells, the numbers of colonies were significantly increased by MYBL2 and FoxM1 over-expressing vector (* \( p < 0.05 \), Fig. 4a.). Conversely, in high-grade glioma U251 cells, the numbers of colonies were reduced by MYBL2 and FoxM1 knockdown (Fig. 4b).

Next, we used MTT to assay the proliferation of U251 cells after transfected with siRNAs. U251 cells generally manifest powerful growth ability and was greatly attenuated by knockdown of MYBL2 and FoxM1 in a time dependent manner, especially at 72 and 96 h (* \( P < 0.05 \)) post transfection of the siRNAs (Fig. 4c). Similar results were found in cell cytomorphology after 48 h down regulation of MYBL2 and FoxM1 (Fig. 4d).

Decreased MYBL2 and FoxM1 inhibit migration, invasion and EMT of glioma cells

Our results showed that MYBL2 and FoxM1 were both upregulated in human glioma and influenced tumor progression. We further estimate the possible correlations of MYBL2 and FoxM1 expression with metastasis and EMT. In vitro, invasion assay was performed in Boyden chambers with the upper wells coated with Matrigel to mimic the extracellular matrix. As shown in Fig. 4e, the number of cells that passed through a Matrigel coated membrane into the lower chamber was lower in U251 cells in silenced groups than NC group (* \( p < 0.05 \)). Then, the scratch assay was conducted to investigate the effects of MYBL2 and FoxM1 on the migratory behaviors of cells in vitro. The degree of wound healing was assessed every 24 h using a microscope, and representative pictures obtained at 48 h for U251 cells are shown (Fig. 4g). Moreover, we found that cells showed diminished adhesion in both MYBL2 and FoxM1 siRNA groups, and a statistical analysis validated that effects were significant when comparing control cells (Fig. 4f).

Next, we detected the expression of EMT markers (E-cadherin, N-cadherin, ZEB1 and Vimentin) by Western blotting. Both MYBL2 and FoxM1 siRNAs down regulated the protein levels of N-cadherin and Vimentin but increased the levels of E-cadherin and ZEB1 (Fig. 4h). We also detected the effects of MYBL2 and FoxM1 on MMP activity which has been closely correlated with degradation of basement membrane and invasion of cancer cells. The results showed that activity of MMP-2 and MMP-9 were decreased compared with control cells (Fig. 4h).

Knockout of MYBL2 and FoxM1 reduce expression of G2/M genes and causes delay of cells in G2

The possible effects of MYBL2 and FoxM1 knockdown on cell cycle progression were assessed by PI staining and flow cytometry. Depletion of MYBL2 and FoxM1 in U251 cells resulted in an increase in cells at the G2/M phase (Fig. 5a and b). The effects of MYB2 and FoxM1 siRNAs on the mRNAs and proteins levels of cell cycle key regulators, including P21, P27, cyclinB1, CDK6, and CDK2 were investigated by Western blotting. As shown in Fig. 5c, the expression of cyclin B and cyclin D down-regulated, but the expression of P21, P27 and CDK6 were up regulated when comparing with NC group. However, MYLB2 and FoxM1 silencing have little effect in CDK2 protein (Fig. 5c).

Table 6 Interaction between MYBL2 expression and radiotherapy on HGG glioma survival

| MYBL2 expression | Radiotherapy | Patients | Deaths | MST (Months) | Adjusted HR (95% CI) | \( P^* \) |
|------------------|--------------|----------|--------|--------------|----------------------|----------|
| High             | Yes          | 136      | 127    | 4.9          |                      | 1        |
| High             | No           | 404      | 292    | 9.6          | 5.29 (1.475-18.969)  | 0.011*   |
| Low              | Yes          | 10       | 8      | 1.5          | 0.995 (0.335-2.958)  | 0.993    |
| Low              | No           | 17       | 12     | 7.7          | 1.769 (0.267-11.697) | 0.554    |

\( ^* \text{p-value}<0.05; \) Abbreviations: MST median survival time

Adjusted for age, gender, race, and history neoadjuvant treatment

Table 7 Interaction between FoxM1 expression and radiotherapy on HGG glioma survival

| FoxM1 expression | Radiotherapy | Patients | Deaths | MST (Months) | Adjusted HR (95% CI) | \( P^* \) |
|------------------|--------------|----------|--------|--------------|----------------------|----------|
| High             | Yes          | 143      | 133    | 4.7          |                      | 1        |
| High             | No           | 413      | 298    | 9.7          | 5.486 (0.939-32.043) | 0.05     |
| Low              | Yes          | 3        | 2      | 1.3          | 0.998 (1.91-5.217)   | 0.99     |
| Low              | No           | 8        | 6      | 3.8          | 0.76 (0.41-14.072)   | 0.85     |

\( ^* \text{p-value}<0.05; \) Abbreviations: MST median survival time

Adjusted for age, gender, race, and history neoadjuvant treatment
Down regulation of MYBL2 and FoxM1 induced cell apoptosis in glioma cells

To determine whether MYBL2 and FoxM1 are associated with apoptosis, U251 cells were transfected with siRNAs for 24, 48 and 72 h, as described above, the number of apoptotic cells was assessed using an Annexin V-FITC/PI and hocheest 3342 staining. As shown in Fig. 6a and b, the percentage of apoptotic cells was increased after 48 h and 72 h. We also tested the effect of MYBL2 and FoxM1 silencing on proteins related to apoptosis including caspase-3/9, Bcl/Bax, PTEN and P53. Western blotting results demonstrated that MYBL2 and FoxM1 down-regulation decreased the expressions of Bcl-2 but increased the expression of Bax. In addition, the protein levels of PTEN and P53 were increased in MYBL2 and FoxM1 siRNAs transfected cells (Fig. 6d). We also conducted caspase-3/9 activity assays and found that knockdown of MYBL2 and FoxM1 induced expression and activity of caspase-3/9 in a time-dependent manner (Fig. 6c).

**MYBL2 and FoxM1 are co-expression in glioma**

Regression analysis showed that MYBL2 and FoxM1 had high correlation coefficients (LGG, \( r = 0.835 \); HGG,
Then, we performed separately for high grade and low-grade glioma using cbioPortal. Results showed that whether in low or high-grade glioma, the expression of MYBL2 and FoxM1 are highly correlated (LGG: Pearson’s correlation = 0.83; HGG: Pearson’s correlation = 0.65) (Fig. 7a). In addition, we examined the heatmap between MYBL2 and FoxM1 using another tool, the Xena browser (Fig. 7b). To further verify the correlation between MYBL2 and FoxM1, we downregulated both MYBL2 and FoxM1 in U251 cells by siRNAs. As shown in Fig. 7c and d, downregulation of MYBL2 did a little change of FoxM1 expression, while MYBL2 expression was dramatically reduced by knockdown of FoxM1 (*p < 0.05). Moreover, Western blotting analyses showed that MYBL2 and FoxM1 co-expression in protein expression. (Fig. 7 e and f). These results indicated that MYBL2 and FoxM1 had high correlation expression both in mRNA and protein levels.

**Down-regulation of Akt induced FoxM1 and MYBL2 expression**

Previous studies showed that FoxM1 was a key downstream gene of the Akt/FoxM1 signaling cascade. Since our results above indicated the correlation of FoxM1 and MYBL2 in glioma progression, we further study the mechanism of MYBL2 and FoxM1 expression in glioma. Therefore, we first tested the basal level of p-Akt in glioma tissues and cell lines using Western blotting. As shown in Fig. 8a and b, over expression of p-Akt was
observed in glioma tissues and glioma cell lines. Then, down-regulation of p-Akt by MK-2206 2HCl (Akt inhibitor, 10 nM), we found that Akt inhibitor dramatically inhibited FoxM1 and MYBL2 mRNA and protein expressions in U251 cells (Fig. 8c-e). Moreover, we found that SC79 (5 μg/mL), the specific Akt activator, increased the expression of FoxM1 and MYBL2 (Fig. 8f). To further characterize the molecular pathway of FoxM1, the online
GeneMANIA tool (http://www.genemania.org/) was used. MYBL2 and GSK3A (a key regulator of Akt pathway) were confirmed interactions with FoxM1. Together, these results indicate MYBL2 is a key downstream regulator of Akt/FoxM1 pathway.

Our analysis strongly supports that the role of MYBL2 and FoxM1 in glioma progression and illustrates that increased FoxM1 activity up-regulates MYBL2 through the Akt/FoxM1 signaling cascade (Fig. 9).

Discussion
In the present study, for the first time, we found that MYBL2 and FoxM1 are significantly associated with glioma progress; meanwhile, MYBL2 is interacted with radiotherapy for glioma survival. We also demonstrated the existence of a significant association between MYBL2 and FoxM1 expression in glioma. Furthermore, our results suggested that MYBL2 was downstream of the Akt/FoxM1 signaling pathway.

Recently, studies found that transcription factors (TFs) and the transcriptional network play important roles in brain tumors progress [25]. In the present study, two transcription factors MYBL2 and FoxM1 emerge as synergistic initiators and master regulators of glioma progress and transformation. We identified both FoxM1 and MYBL2 in high-grade glioma tissues were much higher than in normal brain tissues and low-grade glioma tissues. Either or both overexpression of MYBL2 and FoxM1 were associated with poor prognostic.

The postoperative radiotherapy is an established standard treatment for glioma patients [26]. However, glioblastoma is highly resistant to radiotherapy, which is a common
problem with current anticancer therapies [27]. So having an individualized radiotherapy plan based on each patient's radio sensibility is necessary for increasing the treatment efficacy. Thus, the radio sensibility biomarker(s) can be very useful in glioma radiotherapy. The role of FoxM1 in radiotherapy has been reported in GBM [19, 20, 28], but relatively little is known for MYBL2. In this study, we showed that MYBL2 is interacted with radiotherapy for glioma survival. GBM patients, those with MYBL2 high levels without radiotherapy had a significantly higher death risk than those with radiotherapy. Together, these findings further corroborate the rationale of MYBL2 and FoxM1 targeting in combination with irradiation.

Cell cycle progression and epithelial-mesenchymal transition (EMT) are key steps for tumor progress. Previous research had shown that MYBL2 and FoxM1 were both important cell cycle proliferation factors and might collaborate to induce mitosis [29, 30]. To identify the molecular mechanism for the effects of MYBL2 and FoxM1 in glioma progress, we investigated the role of MYBL2 and FoxM1 in cell cycle progression and EMT. The results showed that knockout of MYBL2 and FoxM1 induced a G2/M phase arrest by down-regulation of cyclin B and cyclin D, but up-regulation of P21, P27 and CDK6. In addition, silencing of MYBL2 and FoxM1 down regulated the protein levels of N-cadherin and Vimentin but

![Fig. 7 Co-expression of MYBL2 and FoxM1 in glioma.](image)

- The analysis was performed by using UCSC Xena.
- Western blotting (c) and RT-qPCR (d) analyze of MYBL2 and FoxM1 expression. e The expression of FoxM1 and MYBL2 were examined by Western blotting in 26 glioma specimens and 1 normal tissue. *P < 0.05 represent the protein levels in MYBL2 or FoxM1 group compared to the NC group. 
increased the levels of E-cadherin and ZEB1. These data indicated that MYBL2 and FoxM1 regulators of glioma progress and transformation by inducing cell cycle proliferation and EMT.

The BMYB-FoxM1 complex frequently observed and played an impotent role in cancers with poor prognosis and thought to promote cancer progression by up regulating the expression of mitotic genes [31, 32]. Further study found that MYBL2 is required as a pioneer factor to enable FoxM1 binding to G2/M gene promoters [29]. But, another report showed that a direct transcriptional regulation of FoxM1 by MYBL2, and a feedback loop

---

**Fig. 8** MYBL2 and FoxM1 are activated by Akt signaling pathway. **a** The baseline expression of p-AKT was determined by Western blotting in 26 glioma specimens and 1 normal tissue. **b** The expression of p-Akt was determined in glioma cell lines using Western blotting analysis. **c-e** U251 cells were treated with PAMK-2206-2HCL for 24 h. The expression of FoxM1 and MYBL2 were detected by immunofluorescence (c) real-time PCR (d) and Western blotting (e). **f** U251 cells were treated with PAMK-2206-2HCl or SC79 for 24 h. The expression of FoxM1 and MYBL2 were detected by western blotting. **g** The molecular functional network map of canonical pathways including coexpression, physical interaction, and predicted networks of FoxM1 analyzed by GeneMANIA (http://genemania.org/) tool. *P < 0.05 represent MYBL2 group vs. NC group; #P < 0.05 represent FoxM1 group vs. NC group.
between the latter and c-Myc, may be governing the replication machinery in ESCs [29, 30]. Consistent with these results, we found that a strong correlation of the co-expression of FoxM1 and MYBL2 were observed in patients with gliomas. To further illuminate the relationship of MYBL2 and FoxM1 in glioma. We knocked down of MYBL2 and FoxM1 by siRNA in glioma cells and found that down-regulation of FoxM1 significantly reduced MYBL2 protein expression; while down regulation of MYBL2 did a little change of FoxM1 expression. These results at least partially suggested that MYBL2 was a target of FoxM1 in glioma cells. But additional metadata is required to identify whether MYBL2 expression crucially regulated by FoxM1 through direct interaction with the MYBL2 promoter.

Studies have shown Akt pathway regulate various cell functions, such as angiogenesis, migration and invasion in glioma [33, 34]. Moreover, it is showed that FoxM1 is a key downstream gene in the Akt signaling cascade [21, 33]. In gastric cancer, Akt/FoxM1 signaling has been reported played an important role in chemotherapy [21]. Wang et al. [35] showed that Akt/FoxM1 axis was downstream of CXCL12 and took part in promoting GBM cell invasion.

What is interesting is that some researchers reported that there is a positive regulatory feedback loop between FoxM1 and the PDGF/Akt signaling pathway, and the loop promotes breast cancer tumorigenesis [36]. However, another research reported that blocking the Akt pathway by Akt-specific kinase inhibitor did not significantly alter FoxM1B transcriptional activity [37]. Herein, we demonstrated that if Akt can regulate MYBL2 and FoxM1 expression in glioma cells. By knocking down p-Akt expression with Akt inhibitor lowered both FoxM1 and MYBL2 expression, and the activator elevated the two genes expression. Therefore, MYBL2 may be downstream of the Akt/ FoxM1 signaling pathway. Moreover, more studies are needed to see if the feedback loop of FoxM1 and Akt signaling pathway plays a role in MYBL2 expression in glioma.

**Conclusion**

In summary, our results suggest that both MYBL2 and FoxM1 over-expression are associated with poor prognosis and EMT in glioma. In cell culture experiments, we find a crosstalk between MYBL2 and the Akt/ FoxM1 signaling pathway. The present study raises the possibility that FoxM1 and MYBL2 may be potential...
targets for cancer therapy as both play crucial roles in glioma progression.

Additional file

**Additional file 1: Table S1.** Association of MYBL2 and FoxM1 expression with patient’s clinicopathological features in high grade glioma. (DOCX 19 kb)

Acknowledgements

The authors sincerely thank Chongzhen Qin, Guochao Mao and Xiaobing Zhang for writing assistance.

Authors’ contributions

XZ, substantial contributions to conception and design, acquisition of data, analysis drafted the manuscript; QLL, collection the glioma tissues and revising the article critically for important intellectual content; YTH, helped for collection the glioma tissues. LHZ, gave some advice for the experiment. HHZ, conceived the study, participated in its design and coordination, and final approval of the version to be published. All authors read and approved the final manuscript.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, People’s Republic of China. 2. Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, Hunan, People’s Republic of China. 3. Department of Neurology, The Brain Hospital of Hunan Province, Changsha 410007, Hunan, People’s Republic of China.

Received: 6 April 2017 Accepted: 26 July 2017

Published online: 07 August 2017

References

1. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rose L, Smirnov IV, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(2):1499–508.

2. Jamal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.

3. Cancer Genome Atlas Research N, Brat DJ, Verhaak RG, Abd-es-Salam K, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, et al. Comprehensive, integrative genomic analysis of diffuse low-grade gliomas. Nat Engl J Med. 2015;372(2):2481–98.

4. Lee TI, Young RA. Transcriptional regulation and its misregulation in disease. Cell. 2013;152(6):1237–51.

5. Wei B, Wang L, Du C, Hu G, Wang L, Jin Y, Kong D. Identification of differentially expressed genes regulated by transcription factors in glioblastomas by bioinformatics analysis. Mol Med Rep. 2015;11(4):2548–54.

6. Oh IH, Reddy EP. The myb gene family in cell growth, differentiation and apoptosis. Oncogene. 1999;18(19):3017–33.

7. Fischer M, Quaas M, Steiner L, Engelhard K. The p53-p21-DREAM-CDE/CHR pathway regulates G2/M cell cycle genes. Nucleic Acids Res. 2016;44(4):164–74.

8. Dolz S, Garcia P, Lloper M, Fuster O, Luna I, Ibáñez M, Gómez L, Lopez M, Such E, Cervera J, et al. Study of the 5427G polymorphism and of MYBL2 variants in patients with acute myeloid leukaemia. Leuk Lymphoma. 2015;1–7.

9. Falabella FS, Stearoyl-CoA desaturase 1 (Sd1) gene overexpression is associated with genetic predisposition to hepatocarcinogenesis in mice and rats. Carcinogenesis. 2002;23(11):1933–6.

10. Tao D, Pan Y, Jiang G, Hu L, Zheng S, Lin H, Cao F. B-Myb regulates snail expression to promote epithelial-to-mesenchymal transition and invasion of breast cancer cell. Med Oncol. 2015;32(1):142.

11. Ren F, Wang L, Shen X, Xiao X, Liu Z, Wei P, Wang Y, Qi P, Shen C, Sheng W, et al. MYBL2 is an independent prognostic marker that has tumor-promoting functions in colorectal cancer. Am J Cancer Res. 2015;5(4):1542–52.

12. Haranuru Z, Asou H, Kihara N, Ozpolat B. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorigenesis of human triple negative breast cancer cells. Oncotarget. 2016;7(13):16619–35.

13. Egawa M, Yoshida Y, Ogura S, Kurasaki T, Kizu T, Furuta K, Kamada Y, Chatani N, Hamano M, Kiso S, et al. Increased expression of Forkhead box M1 transcription factor is associated with clinicopathological features and confers a poor prognosis in human hepatocellular carcinoma. Hepatol Res. 2016.

14. Liu Y, Liu Y, Yuan B, Yin L, Peng Y, Yu X, Zhou W, Gong Z, Liu J, He L, et al. FOXM1 promotes the progression of prostate cancer by regulating PSA gene transcription. Oncotarget. 2017.

15. Wang Y, Zhang W, Wen L, Yang H, Wen M, Yun Y, Zhao L, Zhu X, Tian L, Luo E, et al. FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET–AKT-dependent positive feedback loop. Oncotarget. 2016;7(37):59245–59.

16. Wang D, Hu G, Du Y, Zhang C, Lu Q, Lv N, Luo S. Abrupt activation of hedgehog signaling promotes cell proliferation via the transcriptional activation of forkhead box M1 in colorectal cancer cells. J Exp Clin Cancer Res. 2017;36(1):23.

17. Cheng SX, Yu T, Zhang S. FOXM1 promotes glioma cells progression by up-regulating Axin1 expression. PLoS One. 2013;8(8):e72376.

18. Maachani UB, Shankavaram U, Kramm T, Tofflon PJ, Camphausen K, Tandle AT. FOXM1 and STAT3 interaction confers radioresistance in glioblastoma cells. Oncotarget. 2016;7(47):77365–77.

19. Quan JJ, Song JN, Guo JQ. PARP3 interacts with FOXM1 to confer glioblastoma cell radiosensitivity. Tumor Biol. 2015;36(11):8617–24.

20. Lee Y, Kim KH, Kim DG, Cho H, Kim Y, Rheey J, Shin K, Seo YJ, Choi YS, Lee J, et al. FOXM1 promotes Stemness and radio-resistance of Glioblastoma by regulating the master stem cell regulator Sox2. PLoS One. 2015;10(10):e0137703.

21. Jin H, Park MH, Kim SM. 3,3′-Dilindolylmethane potentiates paclitaxel-induced antitumor effects on gastric cancer cells through the Akt/FOXM1 signaling cascade. Oncol Rep. 2015;33(4):2031–6.

22. Yung WM, Chan DW, Liu WW, Yao KM, Ngy HM. Activation of AMPK inhibits cervical cancer cell growth through AKT/FOXO3a/FOXO1 signaling cascade. BMC Cancer. 2013;13:527.

23. Gao YF, Mao XY, Zhu T, Mao CX, Liu ZK, Wang ZB, Li L, Li X, Yin JY, Zhang W, et al. COL3A1 and SNAP91: novel glioblastoma markers with diagnostic and prognostic value. Oncotarget. 2016;7(43):70494–503.

24. Gu H, Feng J, Wang H, Qian Y, Yang L, Chen J, Jia FL, Shi Y, Lu S, Liu Y. Celastrol Ouicubusin extract inhibits the migration and invasion of glioblastoma cells in vitro. BMC Complement Altern Med. 2016;16(1):387.

25. Cao MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EV, Selman E, Donko S, Molman G, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature. 2010;463(7299):318–25.

26. Minniti G, Filippi AR, Osti MF, Ricardi U. Radiation therapy for older patients with brain tumours. Radiat Oncol. 2017;12(1):101.

27. Sehedic D, Cikankowitz A, Hindre F, Davodeau F, Garcia P, Gancet E. Nanomedicine to overcome radioresistance in glioblastoma stem-like cells and surviving clones. Trends Pharmacol Sci. 2015;36(6):236–52.

28. Zhang N, Wu X, Yang L, Xiao F, Zhang H, Zhou A, Huang Z, Huang S. FOXM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51. Clin Cancer Res. 2012;18(21):5961–71.

29. Down CF, Millour J, Lam EW, Watson RJ. Binding of FoxM1 to G2/M gene promoters is dependent upon B-Myb. Biochim Biophys Acta. 2012;1819(8):855–62.

30. Lorvellec M, Dumon S, Maya-Mendoza A, Jackson D, Frampton J, Garcia P. B-Myb is critical for proper DNA duplication during an unperturbed S phase in mouse embryonic stem cells. Stem Cells. 2010;28(10):1751–9.

31. Sadasivam S, DeCaprio JA. The DREAM complex: master coordinator of cell cycle-dependent gene expression. Nat Rev Cancer. 2013;13(8):585–95.

32. Zha Y, Xia Y, Ding J, Choi JH, Yang L, Dong Z, Yan C, Huang S, Ding HF. ME52 is essential for neuroblastoma cell survival and proliferation by transcriptional control of M-phase progression. Cell Death Disc. 2014;5:e1417.

33. Zhang C, Wang Y, Feng Y, Zhang Y, Ji B, Wang S, Sun Y, Zhu C, Zhang D, Sun Y. Gli1 promotes colorectal cancer metastasis in a Foxm1-dependent manner by activating EMT and PI3K-AKT signalling. Oncotarget. 2016;7(52):86134–47.
34. Liu K, Zhang Q, Lan H, Wang L, Mou P, Shao W, Liu D, Yang W, Lin Z, Lin Q, et al. GCNS potentiates Glioma proliferation and invasion via STAT3 and AKT signaling pathways. Int J Mol Sci. 2015;16(9):21897–910.

35. Wang S, Zhang S, Li J, Xu X, Weng Y, Zheng M, Duyang L, Li F. CXCL12-induced upregulation of FOXM1 expression promotes human glioblastoma cell invasion. Biochem Biophys Res Commun. 2014;447(1):1–6.

36. Yu G, Zhou A, Xue J, Huang C, Zhang X, Kang SH, Chiu WT, Tan C, Xie K, Wang J, et al. FoxM1 promotes breast tumorigenesis by activating PDGFA and forming a positive feedback loop with the PDGF/AKT signaling pathway. Oncotarget. 2015;6(13):11281–94.

37. Zhang M, Liu Y, Gao Y, Li S. Silibinin-induced glioma cell apoptosis by PI3K-mediated but Akt-independent downregulation of FoxM1 expression. Eur J Pharmacol. 2015;765:346–54.